Works matching DE "LAPATINIB"
Results: 281
Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.
- Published in:
- Drug Metabolism Reviews, 2015, v. 47, n. 1, p. 21, doi. 10.3109/03602532.2014.1003648
- By:
- Publication type:
- Article
Dose-sparing effect of lapatinib co-administered with a high-fat enteral nutrition emulsion: preclinical pharmacokinetic study.
- Published in:
- PeerJ, 2023, p. 1, doi. 10.7717/peerj.16207
- By:
- Publication type:
- Article
Comparative Effectiveness of Neoadjuvant Therapy for HER2–Positive Breast Cancer: A Network Meta-Analysis.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 9, p. 1, doi. 10.1093/jnci/dju203
- By:
- Publication type:
- Article
Making Sense of Dual HER2-Targeting in Early Breast Cancer?
- Published in:
- 2014
- By:
- Publication type:
- Editorial
Different chemical proteomic approaches to identify the targets of lapatinib.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2023, v. 38, n. 1, p. 1, doi. 10.1080/14756366.2023.2183809
- By:
- Publication type:
- Article
Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis.
- Published in:
- Systematic Reviews, 2022, v. 11, n. 1, p. 1, doi. 10.1186/s13643-022-02134-9
- By:
- Publication type:
- Article
Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
- Published in:
- Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.00271
- By:
- Publication type:
- Article
Lapatinib-Loaded Nanocapsules Enhances Antitumoral Effect in Human Bladder Cancer Cell.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00203
- By:
- Publication type:
- Article
Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00013
- By:
- Publication type:
- Article
Novel Cytochrome P450-3A4 Enzymatic Nanobiosensor for Lapatinib (a Breast Cancer Drug) Developed on a Poly(anilino-co-4-aminobenzoic Acid-Green-Synthesised Indium Nanoparticle) Platform.
- Published in:
- Biosensors (2079-6374), 2023, v. 13, n. 9, p. 897, doi. 10.3390/bios13090897
- By:
- Publication type:
- Article
Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells.
- Published in:
- Journal of Cancer, 2023, v. 14, n. 18, p. 3477, doi. 10.7150/jca.88446
- By:
- Publication type:
- Article
Metformin synergistically increases the anticancer effects of lapatinib through induction of apoptosis and modulation of Akt/AMPK pathway in SK-BR3 breast cancer cell line.
- Published in:
- Iranian Journal of Basic Medical Sciences, 2021, v. 24, n. 11, p. 1529, doi. 10.22038/IJBMS.2021.58825.13069
- By:
- Publication type:
- Article
Evaluation of Lapatinib and Trastuzumab for Ototoxic Effects.
- Published in:
- Journal of International Advanced Otology, 2015, v. 11, n. 3, p. 207, doi. 10.5152/iao.2015.912
- By:
- Publication type:
- Article
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Regression of brain metastases from breast cancer with eribulin: a case report.
- Published in:
- 2013
- By:
- Publication type:
- Case Study
Lapatinib Ameliorates Experimental Arthritis in Rats.
- Published in:
- Inflammation, 2015, v. 38, n. 1, p. 252, doi. 10.1007/s10753-014-0028-6
- By:
- Publication type:
- Article
Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling.
- Published in:
- BMC Systems Biology, 2015, v. 9, n. 1, p. 1, doi. 10.1186/s12918-014-0135-x
- By:
- Publication type:
- Article
Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo.
- Published in:
- Biological Procedures Online, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s12575-023-00212-3
- By:
- Publication type:
- Article
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.
- Published in:
- Molecular Cancer, 2018, v. 17, p. 1, doi. 10.1186/s12943-018-0797-x
- By:
- Publication type:
- Article
The unexpected effect of the combination of lapatinib and capecitabin in cranial metastasis.
- Published in:
- Journal of Cancer Research & Therapeutics, 2023, v. 19, p. S447, doi. 10.4103/jcrt.jcrt_1440_21
- By:
- Publication type:
- Article
Prolonged overall survival in metastatic gastric cancer treated with ipilimumab and lapatinib.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2014, v. 10, n. 4, p. 368, doi. 10.1111/ajco.12292
- By:
- Publication type:
- Article
Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism.
- Published in:
- Acta Pharmacologica Sinica, 2014, v. 35, n. 6, p. 846, doi. 10.1038/aps.2014.26
- By:
- Publication type:
- Article
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.
- Published in:
- PLoS Computational Biology, 2018, v. 14, n. 1, p. 1, doi. 10.1371/journal.pcbi.1005924
- By:
- Publication type:
- Article
Lapatinib Antagonizes Multidrug Resistance-Associated Protein 1-Mediated Multidrug Resistance by Inhibiting Its Transport Function.
- Published in:
- Molecular Medicine, 2014, v. 21, n. 2, p. 390, doi. 10.2119/molmed.2014.00059
- By:
- Publication type:
- Article
The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib.
- Published in:
- Toxicological Sciences, 2024, v. 197, n. 1, p. 69, doi. 10.1093/toxsci/kfad099
- By:
- Publication type:
- Article
HER2-positive breast cancer - Available anti-HER2 therapies and new agents under investigation.
- Published in:
- Journal of Pre-Clinical & Clinical Research, 2020, v. 14, n. 2, p. 44, doi. 10.26444/jpccr/122068
- By:
- Publication type:
- Article
HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
- Published in:
- Molecular Imaging & Biology, 2021, v. 23, n. 6, p. 930, doi. 10.1007/s11307-021-01619-8
- By:
- Publication type:
- Article
Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 12, p. 2214, doi. 10.3390/jcm8122214
- By:
- Publication type:
- Article
Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines.
- Published in:
- Biomedicines, 2020, v. 8, n. 1, p. 2, doi. 10.3390/biomedicines8010002
- By:
- Publication type:
- Article
Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-57601-x
- By:
- Publication type:
- Article
Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval).
- Published in:
- Drug Safety, 2013, v. 36, n. 5, p. 295, doi. 10.1007/s40264-013-0047-5
- By:
- Publication type:
- Article
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study
- Published in:
- Molecular Oncology, 2012, v. 6, n. 4, p. 437, doi. 10.1016/j.molonc.2012.05.003
- By:
- Publication type:
- Article
Scientific surgery.
- Published in:
- British Journal of Surgery, 2012, v. 99, n. 9, p. 1317, doi. 10.1002/bjs.8904
- Publication type:
- Article
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
- Published in:
- Cell Research, 2014, v. 24, n. 5, p. 542, doi. 10.1038/cr.2014.37
- By:
- Publication type:
- Article
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
- Published in:
- European Journal of Health Economics, 2012, v. 13, n. 5, p. 589, doi. 10.1007/s10198-011-0323-1
- By:
- Publication type:
- Article
Development of Acneiform Rash Does Not Predict Response to Lapatinib Treatment in Patients with Breast Cancer.
- Published in:
- Pharmacotherapy, 2013, v. 33, n. 10, p. 1126, doi. 10.1002/phar.1308
- By:
- Publication type:
- Article
Rapid screening of drug candidates against EGFR/HER2 signaling pathway using fluorescence assay.
- Published in:
- Analytical & Bioanalytical Chemistry, 2018, v. 410, n. 30, p. 7827, doi. 10.1007/s00216-018-1403-1
- By:
- Publication type:
- Article
The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
- Published in:
- Molecular & Cellular Biochemistry, 2015, v. 405, n. 1/2, p. 177, doi. 10.1007/s11010-015-2409-z
- By:
- Publication type:
- Article
Gold-capsuled polymeric nanomedicine for synergistic breast cancer photo-chemotherapy.
- Published in:
- Journal of Nanoparticle Research, 2022, v. 24, n. 12, p. 1, doi. 10.1007/s11051-022-05640-y
- By:
- Publication type:
- Article
Abstracts of Theses Approved for the MSc and PhD Degrees at the Faculty of Medicine, Health Sciences Center, Kuwait University, Kuwait.
- Published in:
- Medical Principles & Practice, 2013, v. 22, n. 6, p. 609, doi. 10.1159/000355033
- Publication type:
- Article
India spurns cancer patents.
- Published in:
- Nature, 2013, v. 500, n. 7462, p. 266, doi. 10.1038/500266a
- By:
- Publication type:
- Article
Synthesis of novel mono- and bis-pyrazolylthiazole derivatives as anti-liver cancer agents through EGFR/HER2 target inhibition.
- Published in:
- BMC Chemistry, 2023, v. 17, n. 1, p. 1, doi. 10.1186/s13065-023-00921-6
- By:
- Publication type:
- Article
QBD-Powered Design and Optimization of Nanostructured Lipid Carriers Loaded with BCS class IV Anticancer Drug.
- Published in:
- Indian Journal of Pharmaceutical Education & Research, 2024, v. 58, p. S828, doi. 10.5530/ijper.58.3s.84
- By:
- Publication type:
- Article
DEVELOPMENT AND VALIDATION OF A GREEN LIQUID CHROMATOGRAPHICDIODE ARRAY DETECTION METHOD FOR SIMULTANEOUS QUANTIFICATION OF CAPECITABINE AND LAPATINIB IN PHARMACEUTICALS USING ANALYTICAL PROCEDURE DEVELOPMENT CONCEPT.
- Published in:
- Indian Drugs, 2023, v. 60, n. 4, p. 65, doi. 10.53879/id.60.04.12814
- By:
- Publication type:
- Article
Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells.
- Published in:
- Korean Journal of Parasitology, 2017, v. 55, n. 5, p. 491, doi. 10.3347/kjp.2017.55.5.491
- By:
- Publication type:
- Article
Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 24, p. 9246, doi. 10.1002/cam4.3528
- By:
- Publication type:
- Article
Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 9, p. 2981, doi. 10.1002/cam4.2943
- By:
- Publication type:
- Article
Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 12, p. 3454, doi. 10.1002/cam4.963
- By:
- Publication type:
- Article